Reports of Biochemistry
and Molecular Biology
Sat, Dec 21, 2024
[Archive]
Volume 12, Issue 4 (Vol.12 No.4 Jan 2024)
rbmb.net 2024, 12(4): 512-521 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abusree Ahmed A, Fayez Hasa S, Ahmed Rashed L, Ragab Abd ELAzem N, Shehata Mohamed R, Mostafa Gharib Mohamed D. The Potential Association Between microRNA 135-5P and p62 and Their Effect on NRF2 Pathway in Multiple Sclerosis. rbmb.net 2024; 12 (4) :512-521
URL: http://rbmb.net/article-1-1188-en.html
URL: http://rbmb.net/article-1-1188-en.html
Azza Abusree Ahmed * 
, Salwa Fayez Hasa , Laila Ahmed Rashed , Noura Ragab Abd ELAzem , Rania Shehata Mohamed , Doaa Mostafa Gharib Mohamed
, Salwa Fayez Hasa , Laila Ahmed Rashed , Noura Ragab Abd ELAzem , Rania Shehata Mohamed , Doaa Mostafa Gharib Mohamed
Medical Biochemistry and Molecular Biology Department, Unit of Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract: (1634 Views)
Background: Multiple Sclerosis (MS) is a prevalent non-traumatic disabling disease affecting young adults, characterized by complexity in its pathogenesis. Nuclear factor erythroid 2-Related Factor 2 (NRF2) serves as a crucial transcriptional regulator of anti-inflammatory and antioxidant enzymes, influenced by the ubiquitous protein p62. It acts as a scaffold directing substrates to autophagosomes. This study aims to explore the potential association between microRNA 135-5p and p62 and their impact on inflammation and oxidative stress through the NRF2 pathway in MS.
Methods: The study included 30 healthy controls and 60 MS patients (relapsing-remitting and secondary progressive). Real-time PCR was employed for the detection of Nrf2, p62, miRNA135-5P, and NF-κB in serum, while p53 levels were determined using ELISA.
Results: Nrf2 and p62 expression was significantly downregulated in the MS group compared to controls. Conversely, miRNA135-5P, NF-κB expression, and P53 levels were significantly elevated in the MS group.
Conclusion: This study reveals a potential association between miRNA 135-5p and p62, indicating their role in the pathogenesis of MS. Results suggest that miRNA 135-5p and p62 may influence inflammation and oxidative stress in MS through the NRF2 pathway, potentially mediated by NF-κB and p53.
Methods: The study included 30 healthy controls and 60 MS patients (relapsing-remitting and secondary progressive). Real-time PCR was employed for the detection of Nrf2, p62, miRNA135-5P, and NF-κB in serum, while p53 levels were determined using ELISA.
Results: Nrf2 and p62 expression was significantly downregulated in the MS group compared to controls. Conversely, miRNA135-5P, NF-κB expression, and P53 levels were significantly elevated in the MS group.
Conclusion: This study reveals a potential association between miRNA 135-5p and p62, indicating their role in the pathogenesis of MS. Results suggest that miRNA 135-5p and p62 may influence inflammation and oxidative stress in MS through the NRF2 pathway, potentially mediated by NF-κB and p53.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2023/06/6 | Accepted: 2023/09/30 | Published: 2024/07/2
Received: 2023/06/6 | Accepted: 2023/09/30 | Published: 2024/07/2
References
1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-180. [DOI:10.1056/NEJMra1401483] [PMID] []
2. Nellessen A, Nyamoya S, Zendedel A, Slowik A, Wruck C, Beyer C, et al. Nrf2 deficiency increases oligodendrocyte loss, demyelination, neuroinflammation and axonal damage in an MS animal model. Metab Brain Dis. 2020;35(2):353-362. [DOI:10.1007/s11011-019-00488-z] [PMID]
3. Brandes MS, Gray NE. NRF2 as a Therapeutic Target in Neurodegenerative Diseases. ASN Neuro. 2020;12:1759091419899782. [DOI:10.1177/1759091419899782] [PMID] []
4. He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020;21(13):4777. [DOI:10.3390/ijms21134777] [PMID] []
5. Bakhtiyari N, Sharifi A, Aftabi Y, Gilani N, Zafari V, Ansarin A, Seyedrezazadeh E. Association Between NOX4 And Nrf2 Genes in Non-Small-Cell Lung Carcinoma: A Case-Control Study. Rep Biochem Mol Biol. 2021l;10(2):327-333. [DOI:10.52547/rbmb.10.2.327] [PMID] []
6. Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019;2019:9372182. [DOI:10.1155/2019/9372182] [PMID] []
7. Zheng K, Hu F, Zhou Y, Zhang J, Zheng J, Lai C, et al. miR-135a-5p mediates memory and synaptic impairments via the Rock2/Adducin1 signaling pathway in a mouse model of Alzheimer's disease. Nat Commun. 2021;12 (1): 1-16. [DOI:10.1038/s41467-021-22196-y] [PMID] []
8. Han D, Dong X, Zheng D, Nao J. MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders. Front Pharmacol. 2020;10:1555. [DOI:10.3389/fphar.2019.01555] [PMID] []
9. Saad El-Din S, Ahmed Rashed L, Eissa M, Eldemery AB, Abdelkareem Mohammed O, Abdelgwad M. Potential Role of circRNA- HIPK3/microRNA-124a Crosstalk in the Pathogenesis of Rheumatoid Arthritis. Rep Biochem Mol Biol. 2022;10(4):527-536. [DOI:10.52547/rbmb.10.4.527] [PMID] []
10. Kim M, Park Y, Kwon Y, Kim Y, Byun J, Jeong MS, et al. MiR-135-5p-p62 Axis Regulates Autophagic Flux, Tumorigenic Potential, and Cellular Interactions Mediated by Extracellular Vesicles During Allergic Inflammation. Front Immunol. 2019;10:738. [DOI:10.3389/fimmu.2019.00738] [PMID] []
11. Valiullina AY, Gomzikova M, Garanina EE, Khaibullin T, Rizvanov A, Bulatov E. Small Molecule p53-MDM2 Inhibitors as Potential Regulators of p53-Dependent Genes Expression in Multiple Sclerosis. Blood. 2017;130(Sup 1):4820.
12. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. [DOI:10.1016/S1474-4422(17)30470-2] [PMID]
13. Chan YH. Biostatistics 102: quantitative data--parametric & non-parametric tests. Singapore Med J. 2003;44(8):391-6.
14. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. [DOI:10.1177/1352458520970841] [PMID] []
15. Pegoretti V, Swanson KA, Bethea JR, Probert L, Eisel ULM, Fischer R. Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxid Med Cell Longev. 2020;2020:7191080. [DOI:10.1155/2020/7191080] [PMID] []
16. Maldonado PP, Guevara C, Olesen MA, Orellana JA, Quintanilla RA, Ortiz FC. Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways. Antioxidants (Basel). 2022;11(6):1146. [DOI:10.3390/antiox11061146] [PMID] []
17. Gureev AP, Sadovnikova IS, Starkov NN, Starkov AA, Popov VN. p62-Nrf2-p62 Mitophagy Regulatory Loop as a Target for Preventive Therapy of Neurodegenerative Diseases. Brain Sci. 2020;10(11):847. [DOI:10.3390/brainsci10110847] [PMID] []
18. Hussein M, Magdy R. MicroRNAs in central nervous system disorders: current advances in pathogenesis and treatment. Egypt J Neurol Psychiatry Neurosurg. 2021; 57(1):1-11. [DOI:10.1186/s41983-021-00289-1]
19. Redondo J, Sarkar P, Kemp K, Heesom KJ, Wilkins A, Scolding NJ, Rice CM. Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis. Stem Cells Transl Med. 2018;7(10):748-758. [DOI:10.1002/sctm.18-0045] [PMID] []
20. Michaličková D, Hrnčíř T, Canová NK, Slanař O. Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis. Eur J Pharmacol. 2020;873:172973. [DOI:10.1016/j.ejphar.2020.172973] [PMID]
21. Hammer A, Waschbisch A, Kuhbandner K, Bayas A, Lee DH, Duscha A, et al. The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. Ann Clin Transl Neurol. 2018;5(6):668-676. [DOI:10.1002/acn3.553] [PMID] []
22. Samir SM, Elalfy M, Nashar EME, Alghamdi MA, Hamza E, Serria MS, Elhadidy MG. Cardamonin exerts a protective effect against autophagy and apoptosis in the testicles of diabetic male rats through the expression of Nrf2 via p62-mediated Keap-1 degradation. Korean J Physiol Pharmacol. 2021;25(4):341-354. [DOI:10.4196/kjpp.2021.25.4.341] [PMID] []
23. Nilsson P, Sekiguchi M, Akagi T, Izumi S, Komori T, Hui K, et al. Autophagy-related protein 7 deficiency in amyloid β (Aβ) precursor protein transgenic mice decreases Aβ in the multivesicular bodies and induces Aβ accumulation in the Golgi. Am J Pathol. 2015;185(2):305-13. [DOI:10.1016/j.ajpath.2014.10.011] [PMID]
24. Bhattacharya A, Parillon X, Zeng S, Han S, Eissa NT. Deficiency of autophagy in dendritic cells protects against experimental autoimmune encephalomyelitis. J Biol Chem. 2014;289(38):26525-26532. [DOI:10.1074/jbc.M114.575860] [PMID] []
25. Biasizzo M, Kopitar-Jerala N. Interplay Between NLRP3 Inflammasome and Autophagy. Front Immunol. 2020;11:591803. [DOI:10.3389/fimmu.2020.591803] [PMID] []
26. Ono M, Komatsu M, Ji B, Takado Y, Shimojo M, Minamihisamatsu T, et al. Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. Aging Cell. 2022;21(7):e13615. [DOI:10.1111/acel.13615] [PMID] []
27. Custer SK, Androphy EJ. Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy. Mol Cell Neurosci. 2014;61:133-40. [DOI:10.1016/j.mcn.2014.06.006] [PMID] []
28. Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm (2020). 2021;2(4):618-653. [DOI:10.1002/mco2.104] [PMID] []
29. Yue Y, Stone S, Lin W. Role of nuclear factor κB in multiple sclerosis and experimental autoimmune encephalomyelitis. Neural Regen Res. 2018;13(9):1507-1515. [DOI:10.4103/1673-5374.237109] [PMID] []
30. Davinelli S, Saso L, D'Angeli F, Calabrese V, Intrieri M, Scapagnini G. Astaxanthin as a Modulator of Nrf2, NF-κB, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications. Molecules. 2022;27(2):502. [DOI:10.3390/molecules27020502] [PMID] []
31. Sivandzade F, Prasad S, Bhalerao A, Cucullo L. NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches. Redox Biol. 2019;21:101059. [DOI:10.1016/j.redox.2018.11.017] [PMID] []
32. Kadkhoda S, Eslami S, Mahmud Hussen B, Ghafouri-Fard S. A review on the importance of miRNA-135 in human diseases. Front Genet. 2022;13:973585. [DOI:10.3389/fgene.2022.973585] [PMID] []
33. Wang Y, Yang Z, Zhang K, Wan Y, Zhou Y, Yang Z. miR-135a-5p inhibitor protects glial cells against apoptosis via targeting SIRT1 in epilepsy. Exp Ther Med. 2021;21(5):431. [DOI:10.3892/etm.2021.9848] [PMID] []
34. Ren R, Wu J, Zhou MY. MiR-135b-5p affected malignant behaviors of ovarian cancer cells by targeting KDM5B. Eur Rev Med Pharmacol Sci. 2020;24(22):11469.
35. Liu C, Pan A, Chen X, Tu J, Xia X, Sun L. MiR-5571-3p and miR-135b-5p, derived from analyses of microRNA profile sequencing, correlate with increased disease risk and activity of rheumatoid arthritis. Clin Rheumatol. 2019;38(6):1753-1765. [DOI:10.1007/s10067-018-04417-w] [PMID]
36. Tao Y, Gao K, Shen B, Zhang K, Zhang Z, Wang C. MicroRNA-135b-5p Downregulation Causes Antidepressant Effects by Regulating SIRT1 Expression. Biochem Genet. 2021;59(6):1582-1598. [DOI:10.1007/s10528-021-10076-5] [PMID]
37. Zhou Y, Cui C, Ma X, Luo W, Zheng SG, Qiu W. Nuclear Factor κB (NF-κB)-Mediated Inflammation in Multiple Sclerosis. Front Immunol. 2020;11:391. [DOI:10.3389/fimmu.2020.00391] [PMID] []
38. Shao L, Chen Z, Soutto M, Zhu S, Lu H, Romero-Gallo J, et al. Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. FASEB J. 2019;33(1):264-274. [DOI:10.1096/fj.201701456RR] [PMID] []
39. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77:557-82. [DOI:10.1146/annurev.biochem.77.060806.091238] [PMID]
40. Feroz, W, Sheikh AMA. Exploring the multiple roles of guardian of the genome: P53. Egypt J Med Hum Genet. 2020; 21, 49. [DOI:10.1186/s43042-020-00089-x]
41. Geismann C, Arlt A, Sebens S, Schäfer H. Cytoprotection "gone astray": Nrf2 and its role in cancer. Onco Targets Ther. 2014;7:1497-518.
42. You A, Nam CW, Wakabayashi N, Yamamoto M, Kensler TW, Kwak MK. Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2. Arch Biochem Biophys. 2011;507(2):356-64. [DOI:10.1016/j.abb.2010.12.034] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
